불임 치료제 시장 규모, 점유율, 동향 및 예측 : 약물 종류별, 투여 경로, 유통 채널, 최종사용자, 지역별(2026-2034년)

The global infertility drugs market size was valued at USD 4.32 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.53 Billion by 2034, exhibiting a CAGR of 4.31% from 2026-2034. North America currently dominates the market, holding a market share of 40.8% in 2025. The region benefits from well-established healthcare infrastructure, supportive government initiatives aimed at expanding fertility treatment access and affordability, increasing insurance mandates covering assisted reproductive technologies, and rising awareness about reproductive health solutions, all contributing to the infertility drugs market share.

The growing prevalence of infertility worldwide, driven by lifestyle changes, delayed parenthood, rising obesity rates, and increasing levels of environmental pollutants, is significantly boosting the demand for infertility drugs across the globe. Additionally, the expanding awareness about reproductive health and the destigmatization of fertility treatments are encouraging more individuals and couples to seek medical assistance for conception. The continuous advancements in assisted reproductive technologies, including in vitro fertilization and intrauterine insemination, are broadening the scope of treatment options available to patients, thereby fueling the infertility drugs market growth. Moreover, the development of novel drug formulations with improved efficacy profiles, reduced side effects, and more convenient administration routes is enhancing patient compliance and treatment outcomes. The rising healthcare expenditure in developing nations and increasing government focus on subsidizing fertility care are also propelling demand forward.

The United States of America has become a prominent geographical location in the global infertility drugs industry because of a number of factors. For example, the country faces a problem of increasing infertility levels, which can be attributed to delayed conception among working-class professionals, increasing obesity levels, and a generally inactive lifestyle that affects reproduction. Legislative policies are also favorable to the growth of the industry, given that currently, 25 states and Washington D.C. mandate some form of insurance coverage for fertility treatment. As a result, the country provides a conducive environment for the growth of the fertility drugs industry. For example, the presence of specialized fertility clinics, the level of awareness among physicians regarding the effectiveness of modern pharmacological interventions, and the infrastructure dedicated to the study of human reproduction all contribute to the growth of the industry.

INFERTILITY DRUGS MARKET TRENDS:

Expanding Government Support and Insurance Coverage

Governments and regulatory bodies across the globe are actively introducing legislative measures to enhance accessibility and affordability of fertility treatments, which is creating a conducive environment for the infertility drugs market. Public health authorities are recognizing infertility as a critical reproductive health concern, leading to the formulation of comprehensive policies that mandate or incentivize insurance coverage for fertility care services. This expanding reimbursement landscape is significantly lowering the financial barriers that previously prevented many individuals and couples from pursuing treatment. For instance, for 2024-2028, the Polish government has launched a state-funded in vitro fertilization (IVF) treatment program. The progressive integration of fertility treatments into national health insurance programs is enabling broader patient access to gonadotropins, aromatase inhibitors, and other essential infertility medications. These supportive regulatory frameworks are accelerating prescription volumes and boosting the commercial viability of advanced fertility drug portfolios.

Advancements in Biosimilar and Novel Formulations

The pharmaceutical industry is witnessing a transformative wave of innovation in fertility drug development, with significant progress in biosimilar introductions and novel hormonal formulations that are reshaping the infertility drugs market outlook. The expiration of patents on established biologic fertility medications has opened pathways for the development of cost-effective biosimilar alternatives that maintain therapeutic equivalence while substantially reducing treatment costs for patients. Concurrently, ongoing research into long-acting injectable formulations, sublingual delivery systems, and combination drug products is enhancing patient convenience and improving treatment adherence during assisted reproductive technology cycles. For instance, in October 2025, Ferring Pharmaceuticals presented positive Phase 3 RITA trial data for follitropin delta, a novel recombinant follicle-stimulating hormone studied across 1,165 women undergoing controlled ovarian stimulation in the United States. These advancements are expanding the therapeutic options available to reproductive endocrinologists and providing patients with more personalized, efficient, and affordable fertility treatment protocols.

Rising Integration of Digital Health Technologies

The infertility drugs market forecast is being positively influenced by the accelerating adoption of digital health technologies in fertility care, including telehealth platforms, wearable monitoring devices, and artificial intelligence-powered treatment optimization tools. The integration of remote consultation capabilities is enabling healthcare providers to monitor patients undergoing ovulation induction and controlled ovarian stimulation cycles without requiring frequent in-clinic visits, improving convenience and expanding geographic access to specialty care. Digital platforms are streamlining prescription management, medication delivery coordination, and real-time dosage adjustment based on patient response data. These technological innovations are enhancing treatment monitoring accuracy, reducing medication errors, and facilitating the broader adoption of fertility drugs across previously underserved populations.

INFERTILITY DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

• Gonadotropin
• Aromatase Inhibitors
• Selective Estrogen Receptor Modulators (SERMs)
• Biguanides
• Others

Gonadotropins hold 28.5% of the market share. Gonadotropins are injectable hormonal preparations containing follicle-stimulating hormone and luteinizing hormone that play a critical role in stimulating ovarian follicular development during assisted reproductive technology cycles. These drugs are widely prescribed for women undergoing in vitro fertilization, intrauterine insemination, and controlled ovarian hyperstimulation protocols, making them an essential component of modern fertility treatment regimens. The segment benefits from continuous pharmaceutical innovation in recombinant and highly purified formulations that offer improved consistency, enhanced bioavailability, and reduced immunogenic responses compared to earlier urinary-derived products. Gonadotropins are administered through subcutaneous or intramuscular routes under close medical supervision, with dosing protocols tailored to individual patient responses monitored through regular ultrasound assessments and hormonal evaluations. The expanding number of fertility clinics globally and the growing adoption of advanced reproductive technologies are driving consistent demand for these products.

Analysis by Route of Administration:

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Oral leads the market with a share of 71.5%. Oral administration represents the most widely adopted route for infertility drug delivery owing to its convenience, non-invasive nature, and suitability for self-administration by patients without requiring clinical supervision or injection training. The oral segment encompasses several first-line fertility medications, including clomiphene citrate and letrozole, which are commonly prescribed for ovulation induction in women with anovulatory infertility and polycystic ovary syndrome. The preference for oral medications stems from their accessibility, favorable cost profile compared to injectable alternatives, and the reduced need for frequent clinic visits during treatment cycles. Patients undergoing initial fertility evaluation and treatment typically begin with oral pharmacotherapy before progressing to more intensive injectable protocols, establishing oral drugs as the foundational treatment approach. The increasing prevalence of conditions requiring ovulation induction and the growing trend of telehealth-facilitated fertility consultations are reinforcing the dominant position of the oral route.

Analysis by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Hospital pharmacies dominate the market, with a share of 45.3%. Hospital pharmacies serve as the primary distribution channel for infertility drugs due to the close integration of pharmaceutical dispensing with clinical fertility services within hospital-based reproductive medicine departments. The majority of assisted reproductive technology procedures, including in vitro fertilization and controlled ovarian stimulation, are performed within hospital settings where specialized pharmacists manage the complex medication protocols required for individualized treatment plans. Hospital pharmacies benefit from their ability to maintain temperature-controlled storage for sensitive biologic medications such as gonadotropins, provide professional guidance on reconstitution and injection techniques, and ensure seamless coordination between prescribing physicians and dispensing pharmacists. The expanding network of fertility centers within hospital systems, the increasing volume of assisted reproductive technology cycles being performed globally, and the requirement for specialized pharmaceutical expertise in managing fertility drug regimens are sustaining the strong market position of hospital pharmacies.

Analysis by End User:

• Male
• Female

Female represents the leading segment, with a market share of 70.5%. The female end-user segment holds the dominant position in the infertility drugs market owing to the broader range of pharmacological interventions available for addressing female reproductive health conditions and the greater prevalence of treatment-seeking behavior among women experiencing conception difficulties. Female infertility encompasses a diverse spectrum of underlying causes, including ovulatory dysfunction, polycystic ovary syndrome, endometriosis, and tubal factor infertility, each requiring specific pharmacological approaches that collectively generate substantial demand for fertility medications. The socio-cultural factors across many regions place greater emphasis on female reproductive health, leading to earlier and more frequent medical consultations and treatment initiation by women compared to men. The expanding availability of ovulation-inducing agents, hormonal support medications for embryo transfer cycles, and progesterone supplementation therapies are further strengthening this segment as new treatment protocols continue to evolve.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America, accounting for 40.8% of the share, holds the leading position in the market. The region is served by an advanced healthcare system, an extensive network of highly specialized fertility centers, and an advanced system of insurance mandates that promote patient access to advanced forms of reproductive therapy. The high adoption of advanced forms of assisted reproductive technology in the US and Canada sustains the high demand for gonadotropins, selective estrogen receptor modulators, and other fertility drugs. The growing number of states with fertility insurance coverage mandates is expanding patient access to fertility therapy and helping to alleviate financial barriers to therapy initiation. The advanced regulatory environment, continuous pharmaceutical innovation in fertility drug formulations, and the growing willingness of employers to offer fertility benefits as part of employee health plans are further supporting the dominant market position of the region. Furthermore, the growing incidence of lifestyle-related infertility risk factors, including delayed childbearing, obesity, and lack of exercise, is supporting steady demand for pharmacological interventions across a wide range of patient demographics.

KEY REGIONAL TAKEAWAYS:

UNITED STATES INFERTILITY DRUGS MARKET ANALYSIS

The United States represents the largest individual market for infertility drugs within North America, driven by escalating infertility rates, a well-established network of reproductive medicine specialists, and evolving healthcare policies that are progressively expanding treatment coverage. The nation's robust pharmaceutical research infrastructure supports the continuous development and commercialization of innovative fertility medications that enhance treatment outcomes for diverse patient populations. Growing public awareness campaigns and destigmatization efforts are encouraging more Americans to seek fertility assistance earlier in their reproductive journeys. For instance, in October 2025, the US government announced an agreement with EMD Serono to offer its complete portfolio of in vitro fertilization therapies at an 84% discount off list prices through a direct purchasing platform. The expanding corporate fertility benefits landscape, with approximately 42% of employers offering some form of fertility services coverage, is creating additional access pathways. The growing integration of telehealth solutions in fertility care delivery is further broadening geographic access to specialized treatment across the country.

EUROPE INFERTILITY DRUGS MARKET ANALYSIS

Europe represents a significant market for infertility drugs, supported by comprehensive public healthcare systems, progressive fertility treatment policies, and increasing government funding for assisted reproductive technologies across the region. The regulatory environment in Europe is particularly favorable for fertility drug adoption, with all European Union member states now providing some level of public funding for in vitro fertilization treatments. For instance, the European Atlas of Fertility Treatment Policies 2024 reported that eight countries within Europe now offer six or more fully funded cycles of IVF or intracytoplasmic sperm injection, demonstrating the region's commitment to expanding treatment accessibility. The presence of leading pharmaceutical companies with strong fertility drug portfolios, combined with extensive clinical research networks and established patient referral pathways, is sustaining consistent growth in the European infertility drugs market. Rising awareness about age-related fertility decline and expanding treatment eligibility criteria are further supporting demand.

ASIA-PACIFIC INFERTILITY DRUGS MARKET ANALYSIS

The Asia-Pacific region is emerging as a rapidly growing market for infertility drugs, driven by rising infertility prevalence due to lifestyle changes, delayed marriages, increasing urbanization, and growing awareness about available fertility treatments. Countries including China, Japan, India, South Korea, and Australia are experiencing significant expansion in their fertility treatment infrastructure and pharmaceutical markets. For instance, approximately 275,000 IVF cycles are performed annually in India, supported by various IVF centers operating across the country. Government policy reforms, such as China's expanded family planning regulations and India's Assisted Reproductive Technology Act of 2021, are creating supportive frameworks for fertility treatment adoption throughout the region.

LATIN AMERICA INFERTILITY DRUGS MARKET ANALYSIS

Latin America is witnessing growing demand for infertility drugs, supported by increasing awareness about reproductive health, expanding healthcare infrastructure, and rising disposable incomes across the region. The growing number of private fertility clinics in major urban centers and the increasing adoption of assisted reproductive technologies are creating new opportunities for infertility drug market expansion. Governments across the region are progressively recognizing infertility as a public health priority, leading to the development of regulatory frameworks that improve treatment quality and standardize care protocols. Additionally, the rising trend of delayed parenthood driven by urbanization and evolving socio-economic dynamics is contributing to higher demand for fertility medications throughout the region.

MIDDLE EAST AND AFRICA INFERTILITY DRUGS MARKET ANALYSIS

The Middle East and Africa region is experiencing a gradual increase in the demand for infertility drugs, driven by rising infertility rates linked to diabetes prevalence, vitamin D deficiency, and changing lifestyle patterns. The region faces unique reproductive health challenges stemming from high rates of chronic metabolic conditions and environmental factors that adversely affect fertility outcomes in both men and women. Increasing government investment in healthcare infrastructure, the expansion of specialized fertility clinics in major cities, and growing patient awareness about available treatment options are supporting market development across the region. Additionally, the rising acceptance of assisted reproductive technologies and the gradual destigmatization of fertility treatments are encouraging more individuals and couples to seek pharmacological interventions for infertility.

COMPETITIVE LANDSCAPE:

The competitive scenario for the infertility drugs market is marked by the dominance of pharmaceutical companies that have a robust portfolio of existing products in the market for gonadotropins, aromatase inhibitors, selective estrogen receptor modulators, and other segments of fertility drugs. The major companies in the market have been undertaking strategic initiatives like drug development, regulatory approvals for new drug formulations, and geographical expansion to strengthen their foothold in the market. The companies have been investing significantly in clinical research for the development of biosimilar fertility drugs, long-acting hormone drugs, and other combination therapies that provide better patient convenience and efficacy. The market has also seen challenges like supply chain challenges for biologic drugs that require temperature control, pricing pressures from healthcare payers, and the need for constant innovation and differentiation in a highly competitive market. Strategic partnerships between pharmaceutical companies and fertility clinics have become a common phenomenon in the market.

The report provides a comprehensive analysis of the competitive landscape in the infertility drugs market with detailed profiles of all major companies, including:

• Abbott Laboratories
• Bayer AG
• Ferring Pharmaceuticals
• Livzon Pharmaceutical Group Inc.
• Mankind Pharma
• Merck & Co. Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Theramex

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the infertility drugs market?

2. What is the future outlook of the infertility drugs market?

3. What are the key factors driving the infertility drugs market?

4. Which region accounts for the largest infertility drugs market share?

5. Which are the leading companies in the global infertility drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Infertility Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Gonadotropin
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Aromatase Inhibitors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Selective Estrogen Receptor Modulators (SERMs)
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Biguanides
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Oral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Intravenous
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Subcutaneous
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Intramuscular
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Male
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Female
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Bayer AG
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Ferring Pharmaceuticals
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Livzon Pharmaceutical Group Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Mankind Pharma
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Merck & Co. Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Merck KGaA
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Novartis AG
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Pfizer Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Sanofi S.A.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Theramex
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio